National Key Research and Development Program of China
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer
Qiao Huang, Bo Pei, Zhimin Gong, Lei Wang et al.
Citations
1 citations
Journal
The Oncologist
Topics
Gastric Cancer Management and Outcomes
Field-Weighted Citation Impact (FWCI)
1.52
article
Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer
Qiao Huang, Bo Pei, Zhimin Gong, Lei Wang, Li Kuang, Xianglin Yuan, Li Sun, Hong Qiu
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
The OncologistVol. 30(7)
Institutions
China Three Gorges University (CN), Hubei University of Arts and Science (CN), The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture (CN), Xiangyang Central Hospital (CN), Dongfeng General Hospital (CN), Tongji Hospital (CN), Huazhong University of Science and Technology (CN)
Funders
Huazhong University of Science and Technology, National Key Research and Development Program of China
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer — Qiao Huang, Bo Pei, et al. · The Oncologist (2025) | TGRS Research Map | TGRS